Abstract
The goal of the treatment of glaucoma is to prevent significant loss of vision of the patient by reducing the IOP. Evidence has been shown to have shown that the reduction in IOP delayed progression, including GAO of normal pressure, 8 and reduced the incidence of GAO in patients with HTO. Randomized studies have shown that for each mmHg reduction in IOP compared to basal values, the probability of progression is reduced by about 10%.
Keywords
Intraocular pressure; Visual field loss; Tafluprost
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tafluprost/timolol en el tractament del glaucoma d’angle obert o la hipertensió ocular. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/3529.2This item appears in following collections
The following license files are associated with this item: